N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide | 1021186-98-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并二恶英
• 英文名称: N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide
• 英文别名: T145；(S)-N-(3-Dibenzo[1,4]dioxin-2-yl-2-oxo-oxazolidin-5-ylmethyl)-acetamide；N-[[(5S)-3-dibenzo-p-dioxin-2-yl-2-oxo-1,3-oxazolidin-5-yl]methyl]acetamide
• CAS: 1021186-98-0
• 化学式: C₁₈H₁₆N₂O₅
• 分子量: 340.335
• InChiKey: CARSFZJMGZOXPN-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  (S)-5-(aminomethyl)-3-(dibenzo[b,e][1,4]dioxin-2-yl)oxazolidin-2-one 、 乙酸酐 在 吡啶 作用下， 反应 21.0h， 以58%的产率得到N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide
  参考文献：
  名称：

  Synthesis of novel oxazolidinone antimicrobial agents

  摘要：

  The oxazolidinone class of antimicrobials represents a promising advance in the fight against resistant Gram-positive bacterial infections. Four novel oxazolidinone antimicrobial compounds, each containing a benzodioxin ring system, have been prepared. The general synthesis of each compound begins with the construction of a benzodioxin ring system containing a nitro substituent that ultimately becomes the nitrogen of the oxazolidinone ring. Three of the compounds utilize high yielding 'click chemistry' in their final step. The antimicrobial activities of the new oxazolidinones have been measured and the MIC against Staphylococcus aureus for one of the antimicrobials was determined to be 2-3 mu g/mL, which is comparable to the well-known oxazolidinone, linezolid. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.11.040

文献信息

• Oxazolidinones and pharmaceutical compositions thereof for treating bacterial infections, including infection of Mycobacterium tuberculosis
  申请人：University of St. Thomas

  公开号：US10870646B2

  公开（公告）日：2020-12-22

  Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.

  公开了式 I 的噁唑烷酮化合物：（I）其盐类、含有它们的抗菌药物组合物，以及使用这些化合物抑制哺乳动物（包括人类）体内细菌生长的方法。
• Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US11040025B2

  公开（公告）日：2021-06-22

  The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

  本发明是一种通过向受试者施用有效量的噁唑烷酮，特别是（N-(((S)-3-(二苯并[b,e][1,4]二噁英-7-基)-2-噁唑烷-5-基)甲基）乙酰胺）或其药学上可接受的盐、溶液或立体异构体来治疗或预防受试者感染结核分枝杆菌的方法。
• US11524002B2
  申请人：The Johns Hopkins University

  公开号：US11524002B2

  公开（公告）日：2022-12-13

  The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

  本发明是一种治疗或预防 结核分枝杆菌 本发明是通过向受试者施用有效量的噁唑烷酮，特别是(N-(((S)-3-(二苯并[b,e][1,4]二噁英-7-基)-2-噁唑烷-5-基)甲基)乙酰胺)或其药学上可接受的盐、溶液或立体异构体，来治疗或预防受试者的结核分枝杆菌感染。
• AN OXAZOLIDINONE FOR TREATMENT OF INFFECTIONS WITH MYCOBACTERIUM TUBERCULOSIS
  申请人：THE JOHNS HOPKINS UNIVERSITY

  公开号：US20200330439A1

  公开（公告）日：2020-10-22

  The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.
• OXAZOLIDINONE FOR TREATMENT OF INFFECTIONS WITH MYCOBACTERIUM TUBERCULOSIS
  申请人：The Johns Hopkins University

  公开号：US20210275505A1

  公开（公告）日：2021-09-09

  The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.